VP of Antibody Development
Opportunity to define and build the pipeline of a category-defining company. High ownership across scientific decision-making. Clear path to CSO.
We usually respond within a day
Antiverse
Engineering the future of antibody drug development to change the course of people’s lives!
Do you want to be part of an ambitious techbio start-up successfully tackling an issue nobody thought possible?
Antiverse is seeking a VP of Antibody Development to lead the progression of Antiverse’s internal and partnered programmes from discovery into in vivo validation and beyond.
This role will ensure that our antibody programmes are translated into robust, well-designed in vivo studies and ultimately into high-quality, partner-ready assets. For the right candidate, this role has a clear path to Chief Scientific Officer, expanding into broader scientific strategy and team leadership.
Join us to grow and evolve with a company transforming drug discovery!
Culture and Values
We believe in the power of autonomy nurtured in a culture with the following values.
People first
We work to make things better for everyone: both on a societal level and a personal level. We will thrive, as a team, as a company and as a society by combining smartness with thoughtfulness across everything we do.
Rigour & agility
We move fast and innovate in our thinking, yet combine this agility with utter rigour and robustness. We are dedicated to delivering rock-solid solutions.
Interdisciplinarity
Our interdisciplinary approach goes deeper than our science. We believe that the best ideas and the most interesting conversations often come from synthesising diverse expertise and experiences.
Dignity & nurture
We fundamentally believe in the value of each individual and the worth of their contribution regardless of the outcome. We believe that we all thrive best in a nurturing environment, and everything in our power is committed to building this supportive culture.
Go where there's a need
We have the potential to transform lives. We will not let ourselves be sidetracked in this calling. We will not fail those whose future we can save.
Role
This role will ensure that our antibody programmes are translated into robust, well-designed in vivo studies and ultimately into high-quality, partner-ready assets.
Own progression of internal and partnered programmes from hit to in vivo validation; define and prioritise pipeline strategy; ensure data-driven decision making.
Design and oversee in vivo studies; work closely with CROs; translate in vitro findings into in vivo hypotheses.
Guide optimisation and ensure candidates are suitable for downstream development and partnering.
Oversee CROs; manage timelines, budgets, and quality; interface with partners.
Contribute to overall strategy; support hiring; evolve into CSO role.
Act as a primary external face of Antiverse’s science; communicate with partners and investors; build and leverage a strong network; represent the company externally.
Budgeting and cost consciousness
12–20+ years in antibody therapeutics/biologics R&D
PhD in a related subject area
Proven track record advancing programmes
Experience managing CROs
Comfortable in a fast-paced environment
Benefits
Competitive base salary - DOE
Stock Options
25 days + public holidays
3 Summer Fridays
Private medical insurance
Flexible working hours
Leadership Training and Coaching
Modern office and lab space in the middle of Cardiff
Allowances for equipment both for home and office
Discounted Gym and Pool membership
Referral Bonus
No recruiters, please.
- Department
- Discovery Team
- Locations
- HQ - Cardiff
About Antiverse
Antiverse was founded by Ben Holland, Murat Tunaboylu and Rowina Westermeir at the Deep Science Ventures Accelerator Programme in 2017. Their objective was to create new enabling technologies in antibody discovery using artificial intelligence that allows for the creation of new therapies against the industry's most challenging targets. Since then, Antiverse has worked with five companies in antibody discovery programmes aimed at several GPCRs, Ion Channels and other challenging targets. In addition, we are developing our own internal pipeline, and have raised around $10.1 million.